The immune system mistakes neurons for invaders and attacks them
For decades, ALS has dismantled human bodies without offering medicine a clear point of intervention in its most common form. Now, researchers at UCLA have found that two existing drugs — one already trusted in the treatment of multiple sclerosis — can quiet the immune system's assault on motor neurons in laboratory conditions, suggesting that the disease's autoimmune dimension may finally be addressable. The discovery does not promise a cure, but it opens a door that has long appeared sealed: the possibility of redirecting tools already in hand toward a disease that has resisted them.
- ALS robs patients of movement, speech, and breath with no approved treatment capable of stopping the immune system's role in its most common form.
- In 90-95% of cases, the body's own immune cells turn on healthy neurons — a mechanism current therapies leave entirely untouched.
- UCLA researchers exposed ALS patient immune cells to two drugs in the lab and watched inflammatory proteins fall in both cases, with effects amplified when one drug was paired with dietary fatty acids.
- The finding creates a plausible clinical pathway: a drug neurologists already prescribe for MS may be repurposed, potentially sparing patients the long wait for entirely novel compounds.
- The team is moving toward broader patient testing and clinical trial approval — cautious steps, but meaningful ones for a disease where any forward motion carries weight.
ALS dismantles the body methodically — muscle control first, then speech, then swallowing, then breath. No cure exists. But a team at UCLA's David Geffen School of Medicine has found laboratory evidence that two drugs can interrupt one of the disease's least-addressed mechanisms: the immune system's attack on its own neurons.
The vast majority of ALS cases — somewhere between nine in ten — are sporadic, meaning they arrive without inherited cause or family history. In these patients, cytotoxic T cells, mast cells, and inflammatory macrophages turn against the very nerve tissue they exist to protect. Current treatments do not touch this autoimmune dimension.
Led by Milan Fiala, the UCLA team exposed immune cells taken from sporadic ALS patients to two substances: dimethyl fumarate, already approved for multiple sclerosis, and H-151, a molecule with demonstrated promise against autoimmune activity in experimental settings. Both reduced levels of cytokines and granzymes — the proteins that drive the inflammatory assault. The effect grew stronger when dimethyl fumarate was combined with epoxyeicosatrienoic acids, fatty compounds found in ordinary food.
The researchers now plan to extend their testing to immune cells from additional ALS patients before seeking approval for human clinical trials. The road from a laboratory result to an approved therapy is long and uncertain. But for patients who have exhausted existing options against a disease with no cure, the possibility that a familiar drug might be repurposed — and perhaps enhanced by something as accessible as dietary fat — represents the kind of narrow opening that medicine is obligated to pursue.
Amyotrophic lateral sclerosis kills neurons in the brain and spinal cord. It steals muscle control first, then speech, then the ability to swallow, then breath itself. There is no cure. But researchers at UCLA have identified a possible path forward—two drugs that appear to quiet the immune system's attack on nerve cells in the most common form of the disease.
ALS comes in two varieties. Familial ALS, inherited through families, accounts for roughly one in twenty cases. The rest—nine in ten—arrive without warning or family history. These sporadic cases have a particular vulnerability: the immune system mistakes the neurons for invaders and attacks them. Cytotoxic T cells, mast cells, and inflammatory macrophages wage war on the very tissue they should protect.
A team led by Milan Fiala at the David Geffen School of Medicine at UCLA took immune cells from patients with sporadic ALS and exposed them to two substances in the laboratory. One was dimethyl fumarate, a drug already approved and in use for multiple sclerosis. The other was a molecule called H-151, which has shown promise in blocking autoimmune responses in experimental models. The question was simple: would either one calm the inflammatory storm?
Both did. When the researchers measured the immune cells after treatment, they found reduced levels of cytokines and granzymes—the chemical messengers and proteins that drive inflammation. The effect was even stronger when dimethyl fumarate was paired with certain fatty acids found in food, compounds called epoxyeicosatrienoic acids. The laboratory results suggested a mechanism: you could potentially interrupt the immune system's attack on ALS neurons using tools already in the medical toolkit.
This matters because current ALS treatments do not address the autoimmune component of sporadic disease. They work on other pathways, leaving the immune attack unblocked. A drug that could suppress that attack might help patients who have exhausted existing options. The researchers now plan to test their findings in immune cells from additional ALS patients, then seek approval to move into human clinical trials. If those trials proceed and succeed, dimethyl fumarate—already familiar to neurologists treating MS—could find a second life as an ALS therapy, possibly combined with dietary fatty acids to amplify its effect. The path from laboratory observation to approved treatment is long, but for a disease with no cure, even a narrow opening is worth pursuing.
Citações Notáveis
Both dimethyl fumarate and H-151 reduced the expression of cytokines and granzymes involved in the inflammatory process— UCLA research team led by Milan Fiala, MD
A Conversa do Hearth Outra perspectiva sobre a história
Why does the immune system attack its own neurons in ALS?
That's the central mystery. In sporadic ALS, something goes wrong with immune tolerance—the system loses the ability to distinguish between threat and self. The neurons become targets.
And these two drugs—they're not new?
Dimethyl fumarate is already prescribed for MS. H-151 is experimental but has worked in lab models. The insight here is recognizing they might work against a different disease mechanism.
What does it mean that the effect was stronger with certain fatty acids?
It suggests you might not need to choose between drug and diet. They appear to work together. That's clinically interesting because it's something patients could actually do.
How far away is a treatment?
They need to test in more patient cells first, then seek trial approval. Years, probably. But the mechanism is clear enough to justify moving forward.
For someone with ALS right now, does this help?
Not immediately. But it opens a door for patients who don't respond to current drugs. That's the population most desperate for options.